Cicarperone is decahydroquinoline derivative with local anesthetic action. In ex vivo models Cicarperone protected anesthetized guinea-pigs against ouabain-induced ventricular fibrillation and increased the lethal dose of ouabain. Unlike most drugs with local anesthetic properties, Cicarperone did not depress contractions in isolated atria but increased them. Cicarperone reduces the spontaneous frequency, maximum follow frequency and conduction velocity of rabbit isolated atria. Cicarperone had no blocking action on the chronotropic or positive inotropic actions of isoprenaline on isolated atrial muscle. In vivo evaluation of Cicarperone in anesthetized dogs shows that Cicarperone caused small dose-related bradycardia and a large dose-related decrease in peripheral vascular resistance. Ciclactate has never been marketed in the US and EU.